インデックス付き
  • Jゲートを開く
  • Genamics JournalSeek
  • アカデミックキー
  • ジャーナル目次
  • 中国国家知識基盤 (CNKI)
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • 雑誌の抄録索引作成ディレクトリ
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

Role of Autologous Bone Marrow Stem Cell Transplantation in the Treatment of Active Ulcerative Colitis

Alaa E Ismail, Mohsen M Maher, Wesam A Ibrahim, Shereen ASaleh, Khaled Makboul, Doaa Zakaria Zaki, Marina Nashed, Nehal Ibrahim and Mohammed Fathy

Background: Stem cell therapy was suggested to improve the quality of life to patients of UC through its powerful immunomodulatory effects and its ability to stimulate regeneration of intestinal mucosa.
Aim of the work: To evaluate autologous bone marrow stem cells transplantation as a treatment option for cases of active ulcerative colitis in comparison with the conventional treatment, and to evaluate its safety and feasibility.
Patients and methods: 10 patients of active ulcerative colitis were intravenously injected with autologous bone marrow mononuclear layer containing stem cell and continued on their conventional treatment. Clinical, laboratory and endoscopic assessment of disease severity were done before and after 3 months after SCT.
Results: There was statistically significant improvement in the number of diarrheal motions, heart rate, ESR, CRP, disease extent and severity after SCT with p value0.026, 0.009, 0.006, 0.012, 0.038 respectively with no recorded side effects or complications.
Conclusion: Bone marrow stem Cell transplantation for patients of ulcerative colitis is a safe and feasible procedure. It can improve the quality of life of the patients as well as the disease activity assessed by clinical assessment, laboratory tests, endoscopic extent and severity.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません